These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14691572)

  • 1. Decreased anticoagulant response to tissue factor pathway inhibitor in patients with venous thromboembolism and otherwise no evidence of hereditary or acquired thrombophilia.
    Bombeli T; Piccapietra B; Boersma J; Fehr J
    Thromb Haemost; 2004 Jan; 91(1):80-6. PubMed ID: 14691572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke.
    Duering C; Kosch A; Langer C; Thedieck S; Nowak-Göttl U
    Thromb Haemost; 2004 Oct; 92(4):707-12. PubMed ID: 15467899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
    Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI).
    Dahm AE; Andersen TO; Rosendaal F; Sandset PM
    J Thromb Haemost; 2005 Apr; 3(4):651-8. PubMed ID: 15842349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor anticoagulant response to tissue factor pathway inhibitor in patients with venous thrombosis.
    Tardy-Poncet B; Tardy B; Laporte S; Mismetti P; Amiral J; Piot M; Reynaud J; Campos L; Decousus H
    J Thromb Haemost; 2003 Mar; 1(3):507-10. PubMed ID: 12871458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state.
    Dahm A; Rosendaal FR; Andersen TO; Sandset PM
    Br J Haematol; 2006 Feb; 132(3):333-8. PubMed ID: 16409298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Anticoagulant Activity of Tissue Factor Pathway Inhibitor Measured by a Novel Functional Assay for Predicting Deep Venous Thrombosis in Trauma Patients: A Prospective Nested Case-Control Study.
    Cao X; Su Y; Zhang W; Zhao H; Wen M; Lu S; Zhao Y; Chen Y; Liu L; Zang X; Wu J
    Clin Appl Thromb Hemost; 2021; 27():10760296211063877. PubMed ID: 34898295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
    Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
    Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism.
    Kwon A; Jo SH; Jo YA; Park JY; Kim M; Kang HJ; Kim HS; Cho HC; Lee YK
    Blood Coagul Fibrinolysis; 2014 Jul; 25(5):416-21. PubMed ID: 24448154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants.
    Liestøl S; Sandset PM; Jacobsen EM; Mowinckel MC; Wisløff F
    Br J Haematol; 2007 Jan; 136(1):131-7. PubMed ID: 17092306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis.
    Dahm A; Van Hylckama Vlieg A; Bendz B; Rosendaal F; Bertina RM; Sandset PM
    Blood; 2003 Jun; 101(11):4387-92. PubMed ID: 12560220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology.
    Zakai NA; Lutsey PL; Folsom AR; Heckbert SR; Cushman M
    Thromb Haemost; 2010 Aug; 104(2):207-12. PubMed ID: 20431849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based indications for thrombophilia screening.
    Lindhoff-Last E; Luxembourg B
    Vasa; 2008 Feb; 37(1):19-30. PubMed ID: 18512539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
    Dennis J; Truong V; Aïssi D; Medina-Rivera A; Blankenberg S; Germain M; Lemire M; Antounians L; Civelek M; Schnabel R; Wells P; Wilson MD; Morange PE; Trégouët DA; Gagnon F
    J Thromb Haemost; 2016 Oct; 14(10):1960-1970. PubMed ID: 27490645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hereditary deficiency of antithrombin III, protein C, protein S and factor XII in 121 patients with venous or arterial thrombosis].
    Miljić P; Rolović Z; Elezović I; Antunović P; Stanojević M; Colović M
    Srp Arh Celok Lek; 1999; 127(1-2):21-7. PubMed ID: 10377836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy.
    Opstad TB; Eilertsen AL; Høibraaten E; Skretting G; Sandset PM
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):516-21. PubMed ID: 20453636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis.
    Fujii M; Hayakawa H; Urano T; Sato A; Chida K; Nakamura H; Takada A
    Thromb Res; 2000 Jul; 99(2):111-7. PubMed ID: 10946084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
    Ariëns RA; Alberio G; Moia M; Mannucci PM
    Thromb Haemost; 1999 Feb; 81(2):203-7. PubMed ID: 10063992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The -33T-->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations.
    Ameziane N; Seguin C; Borgel D; Fumeron F; Moatti D; Alhenc-Gelas M; Grandchamp B; Aiach M; Emmerich J; de Prost D
    Thromb Haemost; 2002 Aug; 88(2):195-9. PubMed ID: 12195688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism.
    Hoke M; Kyrle PA; Minar E; Bialonzcyk C; Hirschl M; Schneider B; Kollars M; Weltermann A; Eichinger S
    Thromb Haemost; 2005 Oct; 94(4):787-90. PubMed ID: 16270631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.